<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-7488</journal-id>
<journal-title><![CDATA[Ciencia en Desarrollo]]></journal-title>
<abbrev-journal-title><![CDATA[Ciencia en Desarrollo]]></abbrev-journal-title>
<issn>0121-7488</issn>
<publisher>
<publisher-name><![CDATA[Universidad Pedagógica y Tecnológica de Colombia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-74882023000200013</article-id>
<article-id pub-id-type="doi">10.19053/01217488.v14.n2.2023.15041</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Inmunoterapia en Melanoma: Rol de TIGIT y LAG-3 en el microambiente inmune antitumoral]]></article-title>
<article-title xml:lang="en"><![CDATA[Inmunoterapia en Melanoma: Rol de TIGIT y LAG-3 en el microambiente inmune antitumoral]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gaona Neira]]></surname>
<given-names><![CDATA[Geidi Catherinne]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salazar Prieto]]></surname>
<given-names><![CDATA[Shanon Daniela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rondón-Lagos]]></surname>
<given-names><![CDATA[Milena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Pedagógica y Tecnológica de Colombia  ]]></institution>
<addr-line><![CDATA[Tunja ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Pedagógica y Tecnológica de Colombia  ]]></institution>
<addr-line><![CDATA[Tunja ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<volume>14</volume>
<numero>2</numero>
<fpage>13</fpage>
<lpage>29</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-74882023000200013&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-74882023000200013&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-74882023000200013&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El melanoma es un tumor maligno que surge por alteraciones de los melanocitos, que desencadenan la pérdida de control de los mecanismos de crecimiento y proliferación celular. Dada la capacidad de células del melanoma de inactivar linfocitos, la inmunoterapia en melanoma se ha enfocado en emplear inhibidores de puntos de control inmunitario (CPI) para contrarrestar la evasión inmune. El activador de linfocitos 3 (LAG-3) y el receptor inhibitorio con dominios Ig e ITIM (TIGIT) son proteínas receptoras del punto de control inmunitario que se expresan en células T. En melanoma se evidencia la sobreexpresión de estos receptores inmunitarios y se asocia con peor pronóstico, por lo que diferentes ensayos clínicos han desarrollado moléculas inhibitorias que conducen al bloqueo conjunto de LAG-3 y TIGIT cuyo uso además de conducir a la reducción de la proliferación y capacidad invasiva del tumor, restaura la actividad de las células T e incrementa la respuesta inmune antitumoral. Sin embargo, la influencia de LAG-3 y TIGIT/Nectina-4 en la actividad inmune antitumoral dentro del microambiente tumoral en melanoma aún no es clara. En esta revisión se describen el rol de los receptores LAG-3 y TIGIT en melanoma, el estado de la monoterapia y la terapia combinada dirigida a estos receptores inmunitarios, la influencia en la respuesta inmune antitumoral y las perspectivas de inmunoterapia dirigidas a LAG-3 y TIGIT/Nectina-4 en melanoma.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Melanoma is a malignant tumor that arises from alterations in the melanocytes, which trigger the loss of control of the mechanisms of cell growth and proliferation. Given the ability of melanoma cells to inactivate lymphocytes, immunotherapy in melanoma has focused on using immune checkpoint inhibitors (ICIs) to counteract immune evasion. Lymphocyte activator 3 (LAG-3) and inhibitory receptor with Ig and ITIM domains (TIGIT) are immune checkpoint receptor proteins that are expressed on T cells. Overexpression of these immunological receptors is evident in melanoma and is associated with worse prognosis, whereby different clinical trials have developed inhibitory molecules (as proven-drugs) that leading to the joint blockage of LAG-3 and TGIT, whose use, in addition to leading to the reduction of tumor proliferation and invasiveness, restores the activity of T cells and increases the antitumor immune response. However, the influence of LAG-3 and TIGIT/Nectin-4 on antitumor immune activity within the tumor microenvironment in melanoma remains unclear. This review describes the role of LAG-3 and TIGIT receptors in melanoma, the status of monotherapy and combination therapy targeting these immune receptors, the influence on the antitumor immune response, and the prospects for LAG-3 targeting immunotherapy. and TIGIT/Nectin-4 in melanoma.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[anticuerpos monoclonales]]></kwd>
<kwd lng="es"><![CDATA[células T]]></kwd>
<kwd lng="es"><![CDATA[terapia antitumoral combinada]]></kwd>
<kwd lng="es"><![CDATA[punto de control inmunitario]]></kwd>
<kwd lng="es"><![CDATA[LAG-3]]></kwd>
<kwd lng="es"><![CDATA[TIGIT]]></kwd>
<kwd lng="en"><![CDATA[monoclonal antibodies]]></kwd>
<kwd lng="en"><![CDATA[combined antitumor therapy]]></kwd>
<kwd lng="en"><![CDATA[LAG-3]]></kwd>
<kwd lng="en"><![CDATA[immune checkpoint]]></kwd>
<kwd lng="en"><![CDATA[TIGIT]]></kwd>
<kwd lng="en"><![CDATA[T cells]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>[1]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Signal pathways of melanoma and targeted therapy. In Signal Transduction and Targeted Therapy]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2021</year>
<volume>6</volume>
<page-range>424</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>[2]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sung]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2021</year>
<volume>71</volume>
<page-range>209-49</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>[3]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gutiérrez-Castañeda]]></surname>
<given-names><![CDATA[L. D.]]></given-names>
</name>
<name>
<surname><![CDATA[Nova]]></surname>
<given-names><![CDATA[J. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Tovar-Parra]]></surname>
<given-names><![CDATA[J.D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review: A systemic review]]></article-title>
<source><![CDATA[Melanoma Res]]></source>
<year>2020</year>
<volume>30</volume>
<page-range>62-70</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>[4]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pistillo]]></surname>
<given-names><![CDATA[M.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Carosio]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Grillo]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Fontana]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Mastracci]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Morabito]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab]]></article-title>
<source><![CDATA[Clin Immunol]]></source>
<year>2020</year>
<volume>215</volume>
<page-range>108-428</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>[5]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gyukity-Sebestyén]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Harmati]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Dobra]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Németh]]></surname>
<given-names><![CDATA[I.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Mihály]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Zvara]]></surname>
<given-names><![CDATA[Á.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Melanoma-derived exosomes induce PD-1 Overexpression and tumor progression via mesenchymal stem cell oncogenic reprogramming]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2019</year>
<volume>10</volume>
<page-range>24-59</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>[6]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mattia]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Puglisi]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Ascione]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Malorni]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Carè]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Matarrese]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies]]></article-title>
<source><![CDATA[Cell Death Dis]]></source>
<year>2018</year>
<volume>9</volume>
<page-range>112</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>[7]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eggermont]]></surname>
<given-names><![CDATA[A.M.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Crittenden]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Wargo]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination immunotherapy development in melanoma]]></article-title>
<source><![CDATA[Am Soc Clin Oncol Educ Book]]></source>
<year>2018</year>
<volume>38</volume>
<page-range>197-207</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>[8]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gutzmer]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Stroyakovskiy]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Gogas]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Robert]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Protsenko]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2020</year>
<volume>395</volume>
<page-range>1835-44</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>[9]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[G.V.]]></given-names>
</name>
<name>
<surname><![CDATA[Arance]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Mortier]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Lorigan]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Blank]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Mohr]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2022</year>
<volume>33</volume>
<page-range>204-15</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>[10]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robert]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[G.V.]]></given-names>
</name>
<name>
<surname><![CDATA[Brady]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Dutriaux]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Giacomo]]></surname>
<given-names><![CDATA[.M. Di]]></given-names>
</name>
<name>
<surname><![CDATA[Mortier]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2020</year>
<volume>38</volume>
<page-range>3937-46</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>[11]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amaral]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Seeber]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Mersi]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Meiwes]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary resistance to PD-1-based immunotherapy-A study in 319 patients with stage IV melanoma]]></article-title>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2020</year>
<volume>12</volume>
<page-range>1027</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>[12]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Relecom]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Merhi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Inchakalody]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Uddin]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Rinchai]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Bedognetti]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity]]></article-title>
<source><![CDATA[J Exp Clin Cancer Res]]></source>
<year>2021</year>
<volume>40</volume>
<page-range>74</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>[13]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chauvin]]></surname>
<given-names><![CDATA[J.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Pagliano]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Fourcade]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Sander]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>2015</year>
<volume>125</volume>
<page-range>2046-58</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>[14]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kawashima]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Inozume]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Kawazu]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ueno]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Nagasaki]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TI-GIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment]]></article-title>
<source><![CDATA[J Immunother Cancer]]></source>
<year>2021</year>
<volume>9</volume>
</nlm-citation>
</ref>
<ref id="B15">
<label>[15]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dillon]]></surname>
<given-names><![CDATA[L.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Wojcik]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Lei]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[McCune]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abstract 1625: Distribution and prevalence of LAG-3 expression in samples of melanoma and gastric/gastroesophageal junction cancer", En: Immunology]]></article-title>
<source><![CDATA[Cancer Research]]></source>
<year>2021</year>
<volume>81</volume>
<page-range>16-25</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>[16]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tawbi]]></surname>
<given-names><![CDATA[H.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Schadendorf]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Lipson]]></surname>
<given-names><![CDATA[E.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Ascierto]]></surname>
<given-names><![CDATA[P.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Matamala]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo Gutiérrez]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2022</year>
<volume>386</volume>
<page-range>24-34</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>[17]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[I.M. Okazaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Okazaki]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[LAG-3: from molecular functions to clinical applications]]></article-title>
<source><![CDATA[J. Immunother Cancer]]></source>
<year>2020</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B18">
<label>[18]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[A.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[X.Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Xiong]]></surname>
<given-names><![CDATA[Y.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[K.F.]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[X.G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immune checkpoint LAG3 and its ligand FGL1 in cancer]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2021</year>
<volume>12</volume>
<page-range>785091</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>[19]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2014</year>
<volume>74</volume>
<page-range>3418-28</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>[20]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amaria]]></surname>
<given-names><![CDATA[R. N.]]></given-names>
</name>
<name>
<surname><![CDATA[Postow]]></surname>
<given-names><![CDATA[M. A.]]></given-names>
</name>
<name>
<surname><![CDATA[Tetzlaff]]></surname>
<given-names><![CDATA[M. T.]]></given-names>
</name>
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[M. I.]]></given-names>
</name>
<name>
<surname><![CDATA[Glitza]]></surname>
<given-names><![CDATA[I. C.]]></given-names>
</name>
<name>
<surname><![CDATA[McQuade]]></surname>
<given-names><![CDATA[J. L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma]]></article-title>
<source><![CDATA[J. Clin Oncol]]></source>
<year>2021</year>
<volume>39</volume>
<page-range>95029502</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>[21]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gestermann]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Saugy]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Martignier]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Tillé]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Fuertes Marraco]]></surname>
<given-names><![CDATA[S.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Zettl]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human auto-logous melanoma/T cell co-cultures]]></article-title>
<source><![CDATA[Onco-immunology]]></source>
<year>2020</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B22">
<label>[22]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[G.V.]]></given-names>
</name>
<name>
<surname><![CDATA[Hodi]]></surname>
<given-names><![CDATA[F.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Lipson]]></surname>
<given-names><![CDATA[E.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Schadendorf]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Ascierto]]></surname>
<given-names><![CDATA[P.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Matamala]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unre-sectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2022</year>
<volume>40</volume>
<page-range>360385360385</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>[23]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnston]]></surname>
<given-names><![CDATA[R.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Comps-Agrar]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Hackney]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Huseni]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function]]></article-title>
<source><![CDATA[Cancer Cell]]></source>
<year>2014</year>
<volume>26</volume>
<page-range>923-37</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>[24]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sumida]]></surname>
<given-names><![CDATA[T.S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Type I Interferon Transcriptional Network Regulates Expression of Coinhibitory Receptors in Human T Cells]]></article-title>
<source><![CDATA[Nature Immunology]]></source>
<year>2022</year>
<volume>23</volume>
<page-range>632-42</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>[25]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruniquel]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genomic Organization of the Human LAG-3/CD4 Locus]]></article-title>
<source><![CDATA[Immunogenetics]]></source>
<year>1997</year>
<volume>47</volume>
<page-range>96-8</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>[26]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biochemical Analysis of the Regulatory T Cell Protein Lymphocyte Activation Gene-3 (LAG-3; CD223)]]></article-title>
<source><![CDATA[The Journal of Immunology]]></source>
<year>2004</year>
<volume>173</volume>
<page-range>6806-12</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>[27]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huard]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cellular Expression and Tissue Distribution of the Human LAG-3-Encoded Protein, an MHC Class II Ligand]]></article-title>
<source><![CDATA[Immunogenetics]]></source>
<year>1994</year>
<volume>39</volume>
<page-range>213-7</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>[28]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mastrangeli]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cloning of Murine LAG-3 by Magnetic Bead Bound Homologous Probes and PCR (Gene-Capture PCR)]]></article-title>
<source><![CDATA[Analytical Biochemistry]]></source>
<year>1996</year>
<volume>241</volume>
<page-range>93-102</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>[29]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Petersen]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Jamie]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overcoming the LAG3 Phase Problem]]></article-title>
<source><![CDATA[Nature Immunology]]></source>
<year>2022</year>
<volume>23</volume>
<page-range>993-5</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>[30]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ming]]></surname>
<given-names><![CDATA[Q.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[LAG3 Ectodomain Structure Reveals Functional Interfaces for Ligand and Antibody Recognition]]></article-title>
<source><![CDATA[Nature Immunology]]></source>
<year>2022</year>
<volume>23</volume>
<page-range>1031-41</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>[31]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Workman]]></surname>
<given-names><![CDATA[C.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-3]]></article-title>
<source><![CDATA[The Journal of Immunology]]></source>
<year>2002</year>
<volume>169</volume>
<page-range>53925395</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>[32]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maeda]]></surname>
<given-names><![CDATA[T.K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Atypical Motifs in the Cytoplasmic Region of the Inhibitory Immune Co-Receptor LAG-3 Inhibit T Cell Activation]]></article-title>
<source><![CDATA[The Journal of Biological Chemistry]]></source>
<year>2019</year>
<volume>294</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>6017-26</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>[33]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Souri]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[LAG3 and Its Ligands Show Increased Expression in High-Risk Uveal Melanoma]]></article-title>
<source><![CDATA[Cancers]]></source>
<year>2021</year>
<volume>13</volume>
<page-range>4445</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>[34]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Andreae]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MHC Class II Signal Transduction in Human Dendritic Cells Induced by a Natural Ligand, the LAG-3 Protein (CD223)]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2003</year>
<volume>102</volume>
<page-range>2130-7</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>[35]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hemon]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis]]></article-title>
<source><![CDATA[The Journal of Immunology]]></source>
<year>2011</year>
<volume>186</volume>
<page-range>51735183</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>[36]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maruhashi]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Okazaki]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[LAG-3 Inhibits the Activation of CD4+ T Cells That Recognize Stable PMHCII through Its Conformation-Dependent Recognition of PMHCII"]]></article-title>
<source><![CDATA[Nature Immunology]]></source>
<year>2018</year>
<volume>19</volume>
<page-range>1415-26</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>[37]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camisaschi]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alternative Activation of Human Plasmacytoid DCs in Vitro and in Melanoma Lesions: Involvement of LAG-3]]></article-title>
<source><![CDATA[The Journal of Investigative Dermatology]]></source>
<year>2014</year>
<volume>134</volume>
<page-range>1893-902</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>[38]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shan]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Progress of Immune Checkpoint LAG-3 in Immunotherapy]]></article-title>
<source><![CDATA[Oncology Letters]]></source>
<year>2020</year>
<volume>20</volume>
<page-range>207</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>[39]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maruhashi]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Daisuke]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Okazaki]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Kenji]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Binding of LAG-3 to Stable Peptide-MHC Class II Limits T Cell Function and Suppresses Autoimmunity and Anti-Cancer Immunity]]></article-title>
<source><![CDATA[Immunity]]></source>
<year>2022</year>
<volume>55</volume>
<page-range>912-924.e8</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>[40]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dustin]]></surname>
<given-names><![CDATA[M.L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Immunological Synapse]]></article-title>
<source><![CDATA[Cancer Immunology Research]]></source>
<year>2014</year>
<volume>2</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1023-33</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>[41]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guy]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[LAG3 Associates with TCR-CD3 Complexes and Suppresses Signaling by Driving Co-Receptor-Lck Dissociation]]></article-title>
<source><![CDATA[Nature Immunology]]></source>
<year>2022</year>
<volume>23</volume>
<page-range>757-67</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>[42]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fibrinogen-like Protein1 Is a Major Immune Inhibitory Ligand of LAG-3]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2019</year>
<volume>176</volume>
<page-range>334-47</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>[43]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kouo]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells]]></article-title>
<source><![CDATA[Cancer Immunology Research]]></source>
<year>2015</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>412-23</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>[44]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bustos]]></surname>
<given-names><![CDATA[S.O.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Galectin-3 Sensitized Melanoma Cell Lines to Vemurafenib (PLX4032) Induced Cell Death through Prevention of Autophagy]]></article-title>
<source><![CDATA[Oncotarget]]></source>
<year>2018</year>
<volume>9</volume>
<page-range>14567-79</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>[45]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Braeuer]]></surname>
<given-names><![CDATA[R.R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Galectin-3 Contributes to Melanoma Growth and Metastasis via Regulation of NFAT1 and Autotaxin]]></article-title>
<source><![CDATA[Cancer Research]]></source>
<year>2012</year>
<volume>72</volume>
<page-range>5757-66</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>[46]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Figueiredo]]></surname>
<given-names><![CDATA[C.R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Loss ofBAP1 Expression Is Associated with an Immunosuppressive Microenvironment in Uveal Melanoma, with Implications for Immunotherapy Development]]></article-title>
<source><![CDATA[The Journal of Pathology]]></source>
<year>2020</year>
<volume>250</volume>
<page-range>420-39</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>[47]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Souri]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Annemijn]]></surname>
<given-names><![CDATA[P.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Wierenga]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[van Weeghel]]></surname>
<given-names><![CDATA[Christiaan]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Loss of BAP1 Is Associated with Upregulation of the NFkB Pathway and Increased HLA Class I Expression in Uveal Melanoma]]></article-title>
<source><![CDATA[Cancers]]></source>
<year>2019</year>
<volume>11</volume>
<page-range>1102</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>[48]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fröhlich]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular, Clinicopathological, and Immune Correlates of LAG3 Promoter DNA Methylation in Melanoma]]></article-title>
<source><![CDATA[EBio-Medicine]]></source>
<year>2020</year>
<volume>59</volume>
<page-range>102962</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>[49]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camisaschi]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Chiara]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[LAG-3 Expression Defines a Subset of CD4(+) CD25(High) Foxp3(+) Regulatory T Cells That Are Expanded at Tumor Sites]]></article-title>
<source><![CDATA[The Journal of Immunology]]></source>
<year>2010</year>
<volume>184</volume>
<page-range>6545-51</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>[50]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wiguna]]></surname>
<given-names><![CDATA[A. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Walden]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of IL-10 and TGF-ß in Melanoma]]></article-title>
<source><![CDATA[Experimental Dermatology]]></source>
<year>2015</year>
<volume>24</volume>
<page-range>209-14</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>[51]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mirlekar]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tumor Promoting Roles of IL-10, TGF-ß, IL-4, and IL-35: Its Implications in Cancer Immunotherapy]]></article-title>
<source><![CDATA[SAGE Open Medicine]]></source>
<year>2022</year>
<volume>10</volume>
<page-range>20</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>[52]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ge]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TIGIT, the next Step towards Successful Combination Immune Checkpoint Therapy in Cancer]]></article-title>
<source><![CDATA[Frontiers in Immunology]]></source>
<year>2021</year>
<volume>12</volume>
<page-range>699-895</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>[53]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reches]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nectin4 Is a Novel TIGIT Ligand Which Combines Checkpoint Inhibition and Tumor Specificity]]></article-title>
<source><![CDATA[Journal for Immunotherapy of Cancer]]></source>
<year>2020</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B54">
<label>[54]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arruga]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Tigit/CD226/CD155 Immunomodulatory Axis Is Deregulated in CLL and Contributes to B-Cell Anergy]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2021</year>
<volume>138</volume>
<page-range>3718</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>[55]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mathew]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[LPA5 Is an Inhibitory Receptor That Suppresses CD8 T-Cell Cytotoxic Function via Disruption of Early TCR Signaling]]></article-title>
<source><![CDATA[Frontiers in Immunology]]></source>
<year>2019</year>
<volume>10</volume>
<page-range>1159</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>[56]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yeo]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TIGIT/CD226 Axis Regulates Anti-Tumor Immunity]]></article-title>
<source><![CDATA[Pharmaceuticals (Basel, Switzerland)]]></source>
<year>2021</year>
<volume>14</volume>
<page-range>200</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>[57]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PD-1+ TIGIT+ CD8+ T Cells Are Associated with Pathogenesis and Progression of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma]]></article-title>
<source><![CDATA[Cáncer Immunology, Immunotherapy: CII]]></source>
<year>2019</year>
<volume>68</volume>
<page-range>2041-54</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>[58]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combined Evaluation of the Expression Status of CD155 and TIGIT Plays an Important Role in the Prognosis of LUAD (Lung Adenocarcinoma)]]></article-title>
<source><![CDATA[International Immunopharmacology]]></source>
<year>2020</year>
<volume>80</volume>
<page-range>106198</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>[59]</label><nlm-citation citation-type="">
<source><![CDATA[Journal for Immunotherapy of Cancer]]></source>
<year>2021</year>
<volume>9</volume>
</nlm-citation>
</ref>
<ref id="B60">
<label>[60]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fourcade]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CD226 Opposes TIGIT to Disrupt Tregs in Melanoma]]></article-title>
<source><![CDATA[JCI Insight]]></source>
<year>2013</year>
<volume>3</volume>
</nlm-citation>
</ref>
<ref id="B61">
<label>[61]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets across Longitudinal Specimens in Treatment-Naïve Melanoma Patients: Implications for Clinical Trials]]></article-title>
<source><![CDATA[Clinical Cancer Research: An Official Journal of the American Association for Cancer Research]]></source>
<year>2019</year>
<volume>25</volume>
<page-range>3247-58</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>[62]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fuhrman]]></surname>
<given-names><![CDATA[C. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226]]></article-title>
<source><![CDATA[The Journal of Immunology]]></source>
<year>2015</year>
<volume>195</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>145-55</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>[63]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Au]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abstract 497: Characterization of TIGIT expression using MultiOmyx TMhyperplexed immunofluorescence assay in solid tumors]]></article-title>
<source><![CDATA[Immunology, American Association for Cancer Research]]></source>
<year>2019</year>
<volume>79</volume>
<page-range>497</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>[64]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inozume]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase]]></article-title>
<source><![CDATA[The Journal of Investigative Dermatology]]></source>
<year>2016</year>
<volume>136</volume>
<page-range>255-63</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>[65]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mahnk]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[H.E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention]]></article-title>
<source><![CDATA[The Journal of Investigative Dermatology]]></source>
<year>2016</year>
<volume>136</volume>
<page-range>9-11</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>[66]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chauvin]]></surname>
<given-names><![CDATA[J.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Mignane]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IL15 Stimulation withTIGIT Blockade Reverses CD155-Mediated NK-Cell Dysfunction in Melanoma]]></article-title>
<source><![CDATA[Clinical Cancer Research: An Official Journal of the American Association for Cancer Research]]></source>
<year>2020</year>
<volume>26</volume>
<page-range>5520-33</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>[67]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stâlhammar]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression of Immune Checkpoint Receptors Indoleamine 2,3-Dioxygenase and T Cell Ig and ITIM Domain in Metastatic versus Nonmetastatic Choroi-dal Melanoma]]></article-title>
<source><![CDATA[Cáncer Medicine]]></source>
<year>2019</year>
<volume>8</volume>
<page-range>2784-92</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>[68]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NECTIN4: A Novel Therapeutic Target for Melanoma]]></article-title>
<source><![CDATA[International Journal of Molecular Sciences]]></source>
<year>2021</year>
<volume>22</volume>
<page-range>976</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>[69]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Maho]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshinao]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nectin Cell Adhesion Molecule 4 (NEC-TIN4) Expression in Cutaneous Squamous Cell Carcinoma: A New Therapeutic Target?"]]></article-title>
<source><![CDATA[Biomedicines]]></source>
<year>2021</year>
<volume>9</volume>
<page-range>355</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>[70]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chocarro]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Landscape of LAG-3-Targeted Therapy]]></article-title>
<source><![CDATA[Immuno-Oncology Technology]]></source>
<year>2022</year>
<volume>14</volume>
<page-range>100079</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>[71]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characterization of a Novel Anti-Human Lymphocyte Activation Gene 3 (LAG-3) Antibody for Cancer Immunotherapy]]></article-title>
<source><![CDATA[MAbs]]></source>
<year>2019</year>
<volume>11</volume>
<page-range>1139-48</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>[72]</label><nlm-citation citation-type="book">
<collab>NIH</collab>
<source><![CDATA[Eftilagimod alpha]]></source>
<year>2022</year>
<publisher-name><![CDATA[National Cancer Institute]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B73">
<label>[73]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Atkinson]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eftilagimod Alpha, a Soluble Lymphocyte Activation Gene-3 (LAG-3) Protein plus Pembrolizumab in Patients with Metastatic Melanoma]]></article-title>
<source><![CDATA[Journal for Immunotherapy of Cancer]]></source>
<year>2020</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B74">
<label>[74]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhai]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Novel Cyclic Peptide Targeting LAG-3 for Cancer Immunotherapy by Activating Antigen-Specific CD8+ T Cell Responses]]></article-title>
<source><![CDATA[Acta Pharmaceutica Sinica. B]]></source>
<year>2020</year>
<volume>10</volume>
<page-range>1047-60</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>[75]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bai]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-LAG-3 Antibody LBL-007 in Combination with Toripalimab in Patients with Unresectable or Metastatic Melanoma: A Phase I, Open-Label, Multicenter, Dose Escalation/Expansion Study]]></article-title>
<source><![CDATA[Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology]]></source>
<year>2022</year>
<volume>40</volume>
<page-range>9538</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>[76]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PD-L1/LAG-3 Bispecific Antibody Enhances Tumor-Specific Immunity]]></article-title>
<source><![CDATA[Oncoimmunology]]></source>
<year>2021</year>
<volume>10</volume>
<page-range>1943180</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>[77]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jorgovanovic]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Roles of IFN-7in Tumor Progression and Regression: A Review]]></article-title>
<source><![CDATA[Biomarker Research]]></source>
<year>2020</year>
<volume>8</volume>
<page-range>49</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>[78]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Norville]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Protease Activata-ble Interleukin-2 Fusion Protein Engenders Antitumor Immune Responses by Interferon Gamma-Dependent and Interferon Gamma-Independent Mechanisms]]></article-title>
<source><![CDATA[Journal of Interferon &amp; Cytokine Research]]></source>
<year>2022</year>
<volume>42</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>316-28</page-range></nlm-citation>
</ref>
<ref id="B79">
<label>[79]</label><nlm-citation citation-type="book">
<collab>FDA</collab>
<source><![CDATA[Burst Edition: FDA approvals of Op-dualag (nivolumab and relatlimabrmbw) for unresectable or metastatic melanoma, and Keytruda (pembrolizumab) for patients with advanced endometrial carcinoma]]></source>
<year>2022</year>
<publisher-loc><![CDATA[U.S. ]]></publisher-loc>
<publisher-name><![CDATA[Food and Drug Administration]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B80">
<label>[80]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamid]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Activity of Fianlimab (REGN3767), a Human Anti-LAG-3 Monoclonal Antibody, Combined with Cemiplimab (Anti-PD-1) in Patients (Pts) with Advanced Melanoma]]></article-title>
<source><![CDATA[Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology]]></source>
<year>2021</year>
<volume>39</volume>
<page-range>9515</page-range></nlm-citation>
</ref>
<ref id="B81">
<label>[81]</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[C.C.]]></given-names>
</name>
</person-group>
<source><![CDATA[387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies]]></source>
<year>2020</year>
<publisher-name><![CDATA[Regular and young investigator award abstracts, BMJ Publishing Group Ltd]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B82">
<label>[82]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schöffski]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase I/II Study of the LAG-3 Inhibitor Ieramilimab (LAG525) ± Anti-PD-1 Spartalizumab (PDR001) in Patients with Advanced Malignancies]]></article-title>
<source><![CDATA[Journal for Immunotherapy of Cancer]]></source>
<year>2022</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B83">
<label>[83]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sung]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[LAG-3xPD-L1 Bispecific Antibody Potentiates Antitumor Responses of T Cells through Dendritic Cell Activation]]></article-title>
<source><![CDATA[Molecular Therapy: The Journal of the American Society of Gene Therapy]]></source>
<year>2022</year>
<volume>30</volume>
<page-range>2800-16</page-range></nlm-citation>
</ref>
<ref id="B84">
<label>[84]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dimitriou]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma]]></article-title>
<source><![CDATA[American Society of Clinical Oncology Educational Book. American Society ofClinical Oncology. Meeting]]></source>
<year>2022</year>
<volume>42</volume>
<page-range>1-22</page-range></nlm-citation>
</ref>
<ref id="B85">
<label>[85]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van den Mooter]]></surname>
<given-names><![CDATA[F. A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Abstract CT118: Preliminary data from Phase I first-in-human study of EOS884448, a novel potent anti-TIGIT antibody, monotherapy shows favorable tolerability profile and early signsof clinical activity in immune-resistant advanced cancers]]></article-title>
<source><![CDATA[Clinical Trials, American Association for Cancer Research]]></source>
<year>2021</year>
<volume>81</volume>
<page-range>118</page-range></nlm-citation>
</ref>
<ref id="B86">
<label>[86]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Niebel]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[DNA Methylation Regulates TIGIT Expression within the Melanoma Microenvironment, Is Prognostic for Overall Survival, and Predicts Progression-Free Survival in Patients Treated with Anti-PD-1 Im-munotherapy]]></article-title>
<source><![CDATA[Clinical Epigenetics]]></source>
<year>2022</year>
<volume>14</volume>
<page-range>50</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>[87]</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Merck]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Dohme]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)]]></source>
<year>2021</year>
<month>a</month>
<publisher-name><![CDATA[Clinical-Trials.gov Identifier: NCT04305041]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B88">
<label>[88]</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Merck]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Dohme]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)]]></source>
<year>2021</year>
<month>b</month>
<publisher-name><![CDATA[Clinical-Trials.gov Identifier: NCT04305054]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B89">
<label>[89]</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Merck]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Dohme]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)]]></source>
<year>2021</year>
<month>c</month>
<publisher-name><![CDATA[ClinicalTrials.gov Identifier: NCT04303169]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B90">
<label>[90]</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diwakar]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma]]></source>
<year>2022</year>
<publisher-name><![CDATA[ClinicalTrials.gov Identifier: NCT05130177]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B91">
<label>[91]</label><nlm-citation citation-type="book">
<collab>iTeos Belgium SA</collab>
<source><![CDATA[Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors (TIG-006)]]></source>
<year>2021</year>
<publisher-name><![CDATA[ClinicalTrials.gov Identifier: NCT05060432]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B92">
<label>[92]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moussa]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date]]></article-title>
<source><![CDATA[Drug Design, Development and Therapy]]></source>
<year>2021</year>
<volume>15</volume>
<page-range>453462</page-range></nlm-citation>
</ref>
<ref id="B93">
<label>[93]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Challita]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Pia]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models]]></article-title>
<source><![CDATA[Cancer Research]]></source>
<year>2016</year>
<volume>76</volume>
<page-range>30033013</page-range></nlm-citation>
</ref>
<ref id="B94">
<label>[94]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bedke]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Moritz]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma]]></article-title>
<source><![CDATA[European Urology]]></source>
<year>2021</year>
<volume>80</volume>
<page-range>257-8</page-range></nlm-citation>
</ref>
<ref id="B95">
<label>[95]</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[A.C.]]></given-names>
</name>
</person-group>
<source><![CDATA[Lag-3, Tim-3, and TI-GIT: Co-Inhibitory Receptors with Specialized Functions in Immune Regulation", Immunity]]></source>
<year>2016</year>
<volume>44</volume>
<page-range>989-1004</page-range></nlm-citation>
</ref>
<ref id="B96">
<label>[96]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harjunpää]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Guillerey]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TIGIT as an Emerging Immune Checkpoint]]></article-title>
<source><![CDATA[Clinical and Experimental Immunology]]></source>
<year>2020</year>
<volume>200</volume>
<page-range>108119</page-range></nlm-citation>
</ref>
<ref id="B97">
<label>[97]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burton]]></surname>
<given-names><![CDATA[B.R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sequential Transcriptional Changes Dictate Safe and Effective Antigen-Specific Immunotherapy]]></article-title>
<source><![CDATA[Nature Communications]]></source>
<year>2014</year>
<volume>5</volume>
</nlm-citation>
</ref>
<ref id="B98">
<label>[98]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[W.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression of Lymphocyte-Activating Gene 3 and T-Cell Immunoreceptor with Immunoglobulin and ITIM Domains in Cutaneous Melanoma and Their Correlation with Programmed Cell Death 1 Expression in Tumor-Infiltrating Lymphocytes]]></article-title>
<source><![CDATA[Journal of the American Academy of Dermatology]]></source>
<year>2019</year>
<volume>81</volume>
<page-range>219-27</page-range></nlm-citation>
</ref>
<ref id="B99">
<label>[99]</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rudd]]></surname>
<given-names><![CDATA[C.E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-Receptor LAG-3 for Enhanced Anti-Tumor Immunity]]></article-title>
<source><![CDATA[Cell Reports]]></source>
<year>2020</year>
<volume>30</volume>
<page-range>2075-2082.e4</page-range></nlm-citation>
</ref>
<ref id="B100">
<label>[100]</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Elraglusib (9-ING-41), a selective small molecule inhibitor of Glycogen Synthase Kinase-3 beta, reduces expressionof immune checkpoint molecules PD-1,TIGIT and LAG-3, and enhances CD8+ T cell cytolytic killing of melanoma cells]]></source>
<year>2022</year>
<publisher-name><![CDATA[Research Square]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
